Jeff Bezos, Amazon’s founder and CEO, said that reducing healthcare’s burden on the economy while improving outcomes for employees and their families would be worth the effort, and the 3 companies had the talented experts with fresh approaches and a long-term orientation that will be key to success.
Amazon, Berkshire Hathaway, and JPMorgan Chase announced that they will partner to form an independent healthcare company to serve their US employees, with the goal to improve US employee satisfaction while reducing overall costs, according to a press release.
The 3 companies said they will pursue this objective through an independent company that is “free from profit-making incentives and constraints.” The new entity will initially focus on technology to provide simplified, high-quality healthcare for their employees and their families, at a reasonable cost.” By bringing together 3 of the world’s leading organizations into this new construct, the group hopes to draw on its combined capabilities and resources to take a fresh approach to the critical healthcare challenges society faces today. Amazon is the world’s largest online retailer; Berkshire Hathaway is a holding company led by the billionaire investor Warren Buffett; and JPMorgan Chase is the largest bank in the United States.
Buffett compared the ballooning costs of healthcare to a “hungry tapeworm” feeding on the American economy. The companies say they are not approaching the problem with ready answers, but they are also not accepting the situation as inevitable. “We share the belief that putting our collective resources behind the country’s best talent can, in time, check the rise in health costs while concurrently enhancing patient satisfaction and outcomes,” said Buffett.
Jeff Bezos, Amazon’s founder and CEO, said that reducing healthcare’s burden on the economy while improving outcomes for employees and their families would be worth the effort, and the 3 companies had the talented experts with fresh approaches and a long-term orientation that will be key to success.
Chairman and CEO of JPMorgan Chase, Jamie Dimon, noted that the 3 companies have extraordinary resources and can potentially help all Americans. “Our people want transparency, knowledge, and control when it comes to managing their healthcare,” he added.
The three partners will focus on their collective 1.1 million employees first before opening to the general market. There are few details available about the new company, but the names of the 3 executives who will be leading the effort at the start were released: Marvelle Sullivan Berchtold, a managing director of JPMorgan Chase; Todd Combs, an investment officer of Berkshire Hathaway; and Beth Galetti, a senior vice president at Amazon.
Analysts said the new entity would face challenges such as assessing risk and other tasks that competing insurers are skilled at, but would be able to hire talent to provide for those needs. According to analyst Andrea Harris of Height Securities, the planned venture into healthcare announced by the 3 companies will target drug makers, wholesalers, pharmacy benefit managers (PBMs), and specialty pharmacies, because that is where scale and efficiencies can have the biggest impact. They are less likely to target managed care firms, where markets are too thin and setting up a care network is expensive and difficult.
Harris noted that if Amazon acquires Express Scripts—the last remaining large-market capitalization PBM—it would be in a strong position to drive down prices.
Mark Merritt, president and CEO of the Pharmaceutical Care Management Association, a trade organization representing American PBMs, is taking a wait-and-see approach. “If they have great ideas, we’d be glad to hear them,” he said. But he cautioned against companies involving themselves in complicated businesses that are not part of their core competency. “I think healthcare solutions are better solved on the back end rather than talking about what people’s aspirations are.”
Wall Street’s reaction to the announcement was a slide in the shares of CVS, UnitedHealth, Aetna, Anthem, and Express Scripts.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.